Can Medicare’s Drug Price Negotiation Lower Your Expenses?

TL/DR –

The Medicare Drug Price Negotiation Program was created by Congress in 2022, enabling Medicare to negotiate prices for certain high-cost prescription drugs. Each year, the Centers for Medicare & Medicaid Services select eligible drugs for negotiation based on factors like total spending and availability of alternatives, setting a Maximum Fair Price (MFP) for each. The U.S. Supreme Court declined to hear appeals challenging the program in 2026, effectively allowing it to continue under existing law.

“`html

Medicare Drug Price Negotiation Program: An Overview

Historically, the power to negotiate prescription drug prices directly with pharmaceutical manufacturers was not within the purview of Medicare. However, this changed when the Inflation Reduction Act of 2022 established the Medicare Drug Price Negotiation Program. Currently, Medicare has the capacity to negotiate prices for select high-cost prescription drugs that fall within the ambit of Medicare Part D. The aim of these negotiations is to determine what is known as Maximum Fair Prices (MFPs), thereby working towards the dual objectives of offering financial relief to Medicare beneficiaries and curbing overall Medicare expenditure.

In 2026, the U.S. Supreme Court elected not to hear the appeals that had been filed against the program, hence upholding lower court decisions and allowing the negotiation program to remain in operation. Despite the media attention attracted by the legal battles, the critical implication for Medicare beneficiaries lies in the continuity of the negotiation program.

Crucial Points to Consider

• The negotiation of prices now applies to select high-cost prescription drugs listed by Medicare.
• Only drugs chosen by the Centers for Medicare & Medicaid Services (CMS) have negotiated prices.
• Every Medicare-covered prescription drug is not subject to negotiation.
• The program extends to include more drugs over time.
• Beneficiaries may experience a reduction in their out-of-pocket prescription costs, subject to their Medicare Part D coverage, following successful price negotiation.
• The decision by the Supreme Court entails that the program will continue to operate under the existing legal framework.

Prescription drugs continue to be a major contributor to healthcare expenditures for a significant proportion of Medicare beneficiaries. Congress took a step towards mitigating these costs by setting up the Medicare Drug Price Negotiation Program in 2022. This was the inaugural instance of Medicare being authorized to negotiate prices for certain high-cost prescription medications that met the eligibility criteria stipulated by the law. Despite facing legal hurdles, the program continues to be operational. Beneficiaries may gain a better understanding of how potential changes could impact their prescription drug costs by familiarizing themselves with the workings of the program.

Understanding the Medicare Drug Price Negotiation Program

The Centers for Medicare & Medicaid Services (CMS) oversees the operation of the Medicare Drug Price Negotiation Program. On an annual basis, CMS selects prescription drugs that meet the eligibility criteria set out in federal law for negotiation. Among the aspects taken into consideration are the total Medicare expenditure on the drug, how long the drug has been available in the market, and the availability of generic or biosimilar alternatives. Following a round of negotiation, CMS determines a Maximum Fair Price (MFP) with the drug manufacturer. The negotiated price then comes into effect, and Medicare Part D plans utilize this price when covering the selected medication. The program is being implemented in stages, with an increasing number of drugs being added to the list of eligible drugs each year.

Who Stands to Benefit?

Primarily, those enrolled in Medicare Part D prescription drug coverage are impacted by the negotiation program. If your Part D plan includes one of the medications selected for negotiation, you may stand to benefit from the negotiated price once it is put into effect. However, your actual savings would depend on various factors such as your Medicare Part D plan, whether you have met your deductible, your plan’s cost-sharing requirements, and whether you take any of the drugs that have been negotiated. It’s important to note that the extent of savings will vary amongst different Medicare beneficiaries owing to their unique prescription needs.

Are All Prescription Drugs Subject to Negotiation?

No. Only specific high-cost drugs that meet the eligibility criteria set by federal law are selected for price negotiation. Most prescription medications do not currently fall under the program. However, CMS steadily adds more drugs to the negotiation process in future cycles.

The Supreme Court’s Ruling

In the aftermath of the establishment of the Medicare Drug Price Negotiation Program, a number of pharmaceutical manufacturers moved court to challenge the law. These challenges were rejected by the lower federal courts. The manufacturers then approached the U.S. Supreme Court to review these decisions. In May 2026, the Supreme Court chose not to hear the appeals. Rather than ruling on the constitutionality of the law itself, the Supreme Court allowed the decisions of the lower courts to stand, thereby allowing the Medicare Drug Price Negotiation Program to continue under the current law.

Implications for Medicare Beneficiaries

The ramifications for Medicare beneficiaries are straightforward:

• The Medicare Drug Price Negotiation Program will remain operational.
• CMS will keep adding more drugs to the pool for future negotiations.
• Prices that have been negotiated till date will remain applicable, and prices from future rounds of negotiation will come into effect as and when they are completed.
• Although Congress could alter the law in the future, the program will continue as scheduled under the current law.

Illustrative Example:

Susan, a Medicare Part D enrollee, takes a medication that has been selected by CMS for price negotiation. Once the negotiated Maximum Fair Price comes into effect, her prescription drug plan utilizes the negotiated price when calculating her share of the prescription cost. Depending on how her plan is structured, and the cost-sharing provisions, Susan may end up paying less out-of-pocket than she would have done prior to the negotiated price. The actual savings would depend on the specific medication and the Medicare Part D plan of the beneficiary.

Common Queries

Does Medicare negotiate prices for all prescription drugs?

No. Medicare only negotiates prices for select drugs that meet the eligibility requirements set out in federal law.

Does this impact Original Medicare?

Primarily, the program impacts drugs covered under Medicare Part D. However, as of 2026, the program also includes certain Medicare Part B drugs, with negotiated prices for these coming into effect in 2028.

Is Congress at liberty to alter the program?

Yes. Since the Medicare Drug Price Negotiation Program was instituted through federal legislation, Congress has the power to amend or repeal the law in the future.

Does the Supreme Court’s decision ward off future legal challenges?

No. The Supreme Court merely declined to review the appeals that had been presented to it. Future legal challenges or legislative changes remain plausible.